News
HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback